Outcome evaluation of dipeptidyl peptidase 4 (DPP4) inhibitors and its combination on glycemic control of type 2 diabetes mellitus patients at Putrajaya Hospital / Nurhamizah Noor Rahim

Introduction: Dipeptidyl Peptidase 4 Inhibitor (DPP4-I) is a relatively new antidiabetic agent, hence the study on glycemic outcome in Malaysian population is still lacking. Currently, there is no study conducted in Putrajaya Hospital to examine the outcome of DPP4-I and its combination on glycemic...

Full description

Saved in:

Bibliographic Details
Main Author:	Noor Rahim, Nurhamizah
Format:	Thesis
Language:	English
Published:	2016
Subjects:	Specialties of internal medicine Diabetes Mellitus
Online Access:	https://ir.uitm.edu.my/id/eprint/26211/1/TM_NURHAMIZAH%20NOOR%20RAHIM%20PH%2017_5.pdf
Tags:	Add Tag No Tags, Be the first to tag this record!

id	my-uitm-ir.26211
record_format	uketd_dc
spelling	my-uitm-ir.262112019-11-28T09:50:34Z Outcome evaluation of dipeptidyl peptidase 4 (DPP4) inhibitors and its combination on glycemic control of type 2 diabetes mellitus patients at Putrajaya Hospital / Nurhamizah Noor Rahim 2016 Noor Rahim, Nurhamizah Specialties of internal medicine Diabetes Mellitus Introduction: Dipeptidyl Peptidase 4 Inhibitor (DPP4-I) is a relatively new antidiabetic agent, hence the study on glycemic outcome in Malaysian population is still lacking. Currently, there is no study conducted in Putrajaya Hospital to examine the outcome of DPP4-I and its combination on glycemic control of Type 2 Diabetes Mellitus (T2DM) patients, response towards DPP4-I and predictors for HbA1c reduction. Objective: To evaluate outcome at week 16, 32 and 52; to determine ADR arises from DPP4-I; and to evaluate predictors for HbA1c reduction at week 52. Method: A retrospective observational study was conducted on 184 T2DM patients that were prescribed with DPP4-I. Paired t-test, ANOVA and linear regression analysis were conducted accordingly. Results: 39.1% of study subjects managed to attain HbA1c value ≤7.0% after 52 weeks of therapy with DPP4-I and its combinations. The mean HbA1c reduction was 0.7% compared to baseline. 70.7% were responsive to the DPP4-I treatment with age at the initiation of DPP4-I, mean HbA1c at baseline and week 52 and mean number of antidiabetics prescribed at baseline and week 52 were significantly different between subgroups. Unresponsive subgroup attained only 0.2% HbA1c reduction at around week 16 compared to significant HbA1c reduction attained by responsive group. 2.7% adverse drug reaction related to DPP4-I was reported. Baseline HbA1c values, HbA1c changes at around week 16 and age were found to be the predictors for HbA1c reduction. Conclusion: The addition of DPP4-I demonstrated moderate glycemic reduction to T2DM patients. However, factors such as adherence towards antidiabetics, diet, physical activity and insulin intensification that was not assessed in this study may also influence this effect. 2016 Thesis https://ir.uitm.edu.my/id/eprint/26211/ https://ir.uitm.edu.my/id/eprint/26211/1/TM_NURHAMIZAH%20NOOR%20RAHIM%20PH%2017_5.pdf text en public masters Universiti Teknologi MARA Faculty of Pharmacy, Universiti Teknologi MARA
institution	Universiti Teknologi MARA
collection	UiTM Institutional Repository
language	English
topic	Specialties of internal medicine Diabetes Mellitus
spellingShingle	Specialties of internal medicine Diabetes Mellitus Noor Rahim, Nurhamizah Outcome evaluation of dipeptidyl peptidase 4 (DPP4) inhibitors and its combination on glycemic control of type 2 diabetes mellitus patients at Putrajaya Hospital / Nurhamizah Noor Rahim
description	Introduction: Dipeptidyl Peptidase 4 Inhibitor (DPP4-I) is a relatively new antidiabetic agent, hence the study on glycemic outcome in Malaysian population is still lacking. Currently, there is no study conducted in Putrajaya Hospital to examine the outcome of DPP4-I and its combination on glycemic control of Type 2 Diabetes Mellitus (T2DM) patients, response towards DPP4-I and predictors for HbA1c reduction. Objective: To evaluate outcome at week 16, 32 and 52; to determine ADR arises from DPP4-I; and to evaluate predictors for HbA1c reduction at week 52. Method: A retrospective observational study was conducted on 184 T2DM patients that were prescribed with DPP4-I. Paired t-test, ANOVA and linear regression analysis were conducted accordingly. Results: 39.1% of study subjects managed to attain HbA1c value ≤7.0% after 52 weeks of therapy with DPP4-I and its combinations. The mean HbA1c reduction was 0.7% compared to baseline. 70.7% were responsive to the DPP4-I treatment with age at the initiation of DPP4-I, mean HbA1c at baseline and week 52 and mean number of antidiabetics prescribed at baseline and week 52 were significantly different between subgroups. Unresponsive subgroup attained only 0.2% HbA1c reduction at around week 16 compared to significant HbA1c reduction attained by responsive group. 2.7% adverse drug reaction related to DPP4-I was reported. Baseline HbA1c values, HbA1c changes at around week 16 and age were found to be the predictors for HbA1c reduction. Conclusion: The addition of DPP4-I demonstrated moderate glycemic reduction to T2DM patients. However, factors such as adherence towards antidiabetics, diet, physical activity and insulin intensification that was not assessed in this study may also influence this effect.
format	Thesis
qualification_level	Master's degree
author	Noor Rahim, Nurhamizah
author_facet	Noor Rahim, Nurhamizah
author_sort	Noor Rahim, Nurhamizah
title	Outcome evaluation of dipeptidyl peptidase 4 (DPP4) inhibitors and its combination on glycemic control of type 2 diabetes mellitus patients at Putrajaya Hospital / Nurhamizah Noor Rahim
title_short	Outcome evaluation of dipeptidyl peptidase 4 (DPP4) inhibitors and its combination on glycemic control of type 2 diabetes mellitus patients at Putrajaya Hospital / Nurhamizah Noor Rahim
title_full	Outcome evaluation of dipeptidyl peptidase 4 (DPP4) inhibitors and its combination on glycemic control of type 2 diabetes mellitus patients at Putrajaya Hospital / Nurhamizah Noor Rahim
title_fullStr	Outcome evaluation of dipeptidyl peptidase 4 (DPP4) inhibitors and its combination on glycemic control of type 2 diabetes mellitus patients at Putrajaya Hospital / Nurhamizah Noor Rahim
title_full_unstemmed	Outcome evaluation of dipeptidyl peptidase 4 (DPP4) inhibitors and its combination on glycemic control of type 2 diabetes mellitus patients at Putrajaya Hospital / Nurhamizah Noor Rahim
title_sort	outcome evaluation of dipeptidyl peptidase 4 (dpp4) inhibitors and its combination on glycemic control of type 2 diabetes mellitus patients at putrajaya hospital / nurhamizah noor rahim
granting_institution	Universiti Teknologi MARA
granting_department	Faculty of Pharmacy, Universiti Teknologi MARA
publishDate	2016
url	https://ir.uitm.edu.my/id/eprint/26211/1/TM_NURHAMIZAH%20NOOR%20RAHIM%20PH%2017_5.pdf
_version_	1783733887136956416

Outcome evaluation of dipeptidyl peptidase 4 (DPP4) inhibitors and its combination on glycemic control of type 2 diabetes mellitus patients at Putrajaya Hospital / Nurhamizah Noor Rahim

Similar Items